Risk stratification and surveillance of targeted therapy in blood cancer through proteomics
- Prosjektnummer
- 911730
- Ansvarlig person
- Bjørn Tore Gjertsen
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Blood, Cancer
- Forskningsaktivitet
- 1. Underpinning, 5. Treatment Developement
Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
Mol Imaging Biol 2014 Feb;16(1):53-62.
PMID: 23877869
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course.
Leuk Lymphoma 2014 Sep;55(9):2114-9. Epub 2014 jan 24
PMID: 24255981
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.
Leukemia 2014 Aug;28(8):1738-42. Epub 2014 feb 27
PMID: 24573384
Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.
PLoS One 2014;9(2):e88632. Epub 2014 feb 19
PMID: 24586361
First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.
PLoS One 2014;9(3):e89527. Epub 2014 mar 4
PMID: 24594904
[Towards a more specific cancer treatment?].
Tidsskr Nor Laegeforen 2014 May 27;134(10):1017. Epub 2014 mai 27
PMID: 24865702
Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia.
Mol Cancer 2014;13():116. Epub 2014 mai 21
PMID: 24885082
Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.
Proteomics 2014 Sep;14(17-18):1971-6. Epub 2014 aug 8
PMID: 25044641
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Eur J Haematol 2014 Aug 1. Epub 2014 aug 1
PMID: 25082346
SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute Myeloid Leukemia stem cells.
Cell Stem Cell 2014 Oct 2;15(4):431-46.
PMID: 25280219
Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients.
Cancer Immunol Immunother 2015 Mar;64(3):337-47. Epub 2014 nov 22
PMID: 25416072
Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells.
Oncoscience 2014;1(8):529-39. Epub 2014 aug 6
PMID: 25594060
Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.
Oncotarget 2015 Feb 20;6(5):2794-811.
PMID: 25605239
Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?
Curr Cancer Drug Targets 2013 Jan;13(1):30-47.
PMID: 22873213
Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer.
Cancer Res 2013 Feb 15;73(4):1276-86. Epub 2012 des 10
PMID: 23233739
Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Blood 2013 Feb 14;121(7):e34-42. Epub 2012 des 12
PMID: 23243270
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.
Cancer Immunol Immunother 2013 Apr;62(4):773-85. Epub 2012 des 22
PMID: 23263452
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Leukemia 2013 Jul;27(7):1520-6. Epub 2013 jan 18
PMID: 23328954
Expression of TP53 isoforms p53ß or p53? enhances chemosensitivity in TP53(null) cell lines.
PLoS One 2013;8(2):e56276. Epub 2013 feb 11
PMID: 23409163
Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis.
Cell Death Dis 2013;4():e516. Epub 2013 feb 28
PMID: 23449452
cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases.
Int J Oncol 2013 May;42(5):1815-21. Epub 2013 mar 8
PMID: 23483263
Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors.
Expert Opin Investig Drugs 2013 May;22(5):551-63.
PMID: 23586877
Tunneling nanotube (TNT) formation is independent of p53 expression.
Cell Death Differ 2013 Aug;20(8):1124. Epub 2013 jun 14
PMID: 23764777
Gel2DE - a software tool for correlation analysis of 2D gel electrophoresis data.
BMC Bioinformatics 2013;14():215. Epub 2013 jul 6
PMID: 23829206
Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen.
BMC Cancer 2013;13():341. Epub 2013 jul 11
PMID: 23841896
Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine.
BMC Pharmacol Toxicol 2013;14():35. Epub 2013 jul 11
PMID: 23845085
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
Clin Epigenetics 2013;5(1):12. Epub 2013 jul 30
PMID: 23898968
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.
Clin Epigenetics 2013;5(1):13. Epub 2013 aug 1
PMID: 23915396
Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.
Cancer Discov 2013 Dec;3(12):1416-29. Epub 2013 sep 20
PMID: 24056683
Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid.
Expert Rev Proteomics 2012 Dec;9(6):595-8.
PMID: 23256670
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
PLoS One 2012;7(11):e48992. Epub 2012 nov 14
PMID: 23155442
Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting.
J Proteomics 2012 Dec;76 Spec No.():69-78. Epub 2012 jul 26
PMID: 22842154
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Eur J Clin Invest 2012 Sep;42(9):1016-26. Epub 2012 mai 1
PMID: 22548456
Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
Expert Opin Investig Drugs 2012 May;21(5):587-603. Epub 2012 mar 17
PMID: 22424119
Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines.
Cell Biol Toxicol 2012 Aug;28(4):201-12. Epub 2012 mar 16
PMID: 22422053
Human cells and the Norwegian Health Research Act.
Tidsskr Nor Laegeforen 2012 Mar;132(5):540-2.
PMID: 22398774
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation.
Cell Death Differ 2012 Aug;19(8):1381-9. Epub 2012 mar 2
PMID: 22388350
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Am J Hematol 2012 Apr;87(4):368-76. Epub 2012 feb 28
PMID: 22374841
Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
Mult Scler 2012 Aug;18(8):1116-24. Epub 2012 jan 27
PMID: 22287540
Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status--consequences and potentials for pharmacological intervention.
Br J Haematol 2012 Feb;156(4):468-80. Epub 2011 des 13
PMID: 22150087
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
Leukemia 2012 May;26(5):910-7. Epub 2011 nov 8
PMID: 22064349
Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia.
Oncogene 2012 Mar;31(12):1533-45. Epub 2011 aug 22
PMID: 21860418
Expression and function of p53 full-length, p53beta and p53gamma protein isoforms in cancer
- Disputert:
- januar 2013
- Hovedveileder:
- Bjørn Tore Gjertsen
Risk stratification and therapy response monitoring by phosphor-protein profiles in acute myeloid leukemia
- Disputert:
- august 2013
- Hovedveileder:
- Bjørn Tore Gjertsen
Disease-stabilizing treatment of human acute myeloid leukaemia – experimental and clinical studies
- Disputert:
- januar 2013
- Hovedveileder:
- Øystein Bruserud
Molecular imaging for cancer diagnostics and targeted therapy
- Disputert:
- april 2012
- Hovedveileder:
- Bjørn Tore Gjertsen
Preclinical development of novel therapies against acute myeloid leukaemia
- Disputert:
- april 2012
- Hovedveileder:
- Bjørn Tore Gjertsen
Preclinical tumor visualization and functional characterization of p53 isoforms in cancer
- Disputert:
- mai 2012
- Hovedveileder:
- Emmet Mc Cormack
p53 activating therapy in acute myeloid leukemia
- Disputert:
- august 2012
- Hovedveileder:
- Bjørn Tore Gjertsen
Phosphoproteomics in disease stratification and therapy design of acute myeloid leukemia
- Disputert:
- november 2012
- Hovedveileder:
- Bjørn Tore Gjertsen
- Bjørn Tore Gjertsen Prosjektleder
- Katarina M. Jørgensen Prosjektdeltaker
- Maria Omsland Ph.d.-kandidat
- Calum Leitch Ph.d.-kandidat
- Vibeke Andresen Prosjektdeltaker
- Rakel Brendsdal Forthun Postdoktor
- Sigrun Margrethe Hjelle Postdoktor
- Andre Sulen Ph.d.-kandidat
- Jørn Skavland Postdoktor
- Siv Lise Bedringaas Prosjektdeltaker
- Wenche Hauge Eilifsen Prosjektdeltaker
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest